Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2... Downloaded from https://academic.oup.com/ndt/article/33/7/1280/4995217 by DeepDyve user on 13 July 2022 Nephrol Dial Transplant (2018) 33: 1280 doi: 10.1093/ndt/gfy135 Advance Access publication 11 May 2018 Erratum Claire C.J. Dekkers, David C. Wheeler, C. David Sjo¨stro¨m, Bergur V. Stefansson, Valerie Cain and Hiddo J.L. Heerspink Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kid- ney disease, Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350 In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The num- bers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapa- gliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected. The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] 1280 ERRATUM http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nephrology Dialysis Transplantation Oxford University Press

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Download PDF
1 page

Loading next page...
 
/lp/ou_press/erratum-FeWRFvXPle

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
Copyright © 2022 European Renal Association
ISSN
0931-0509
eISSN
1460-2385
DOI
10.1093/ndt/gfy135
Publisher site
See Article on Publisher Site

Abstract

Downloaded from https://academic.oup.com/ndt/article/33/7/1280/4995217 by DeepDyve user on 13 July 2022 Nephrol Dial Transplant (2018) 33: 1280 doi: 10.1093/ndt/gfy135 Advance Access publication 11 May 2018 Erratum Claire C.J. Dekkers, David C. Wheeler, C. David Sjo¨stro¨m, Bergur V. Stefansson, Valerie Cain and Hiddo J.L. Heerspink Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kid- ney disease, Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350 In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The num- bers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapa- gliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected. The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] 1280 ERRATUM

Journal

Nephrology Dialysis Transplantation – Oxford University Press

Published: Jul 1, 2018

There are no references for this article.